Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
U.S. overhauls childhood vaccine schedule, recommends fewer shots - 2Don't miss Jupiter shining close to the waning gibbous moon on Dec. 7
- 3French ship crosses Strait of Hormuz in first Western European transit during Iran war
- 4California warns of death cap mushrooms outbreak resulting in 3 deaths
- 5'Malcolm in the Middle' reboot releases 1st trailer, reuniting Frankie Muniz and Bryan Cranston: Watch here
- India's top court hears challenges to ruling on women's entry into temple
- Heavenly Pastry Confrontation: Pick Your #1 Sweet Treat!
- From a new flagship space telescope to lunar exploration, global cooperation – and competition – will make 2026 an exciting year for space
- Well known Tea Brands for Each Tea Sweetheart
- Takeaways from AP’s report on potential impacts of Alaska’s proposed Ambler Access Road
- Must-See Attractions in Australia
- The face is familiar, the name might not be. The king of "Hey, it's that guy!' roles is ready to show you his next act.
- Wisconsin archaeologists identify 16 ancient canoes in a prehistoric lake 'parking lot'
- Desired Travel Objections Worldwide: Where to Go Straightaway
